Commentary on potential benefit to Neuren of RPD designation
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Rare Pediatric Disease designation received from FDA
- Appendix 4E and 2019 full year accounts
- Update on trofinetide Phase 3 trial in Rett syndrome
- 2019 year-end update and 2020 outlook
- Patent to 2034 granted in Europe for Neurens NNZ-2591
Later from Neuren Pharmaceuticals
- Compelling results for 2591 dose ranging study in PMS model
- Neuren to capture substantially greater value after Phase 3
- Temporary pause in new enrolments for LAVENDER trial in US
- First patent in Israel granted for trofinetide
- Q1 2020 Activity Report
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals